Ganymed’s IMAB362 Receives Orphan Drug Designation from FDA and EMA

News   Oct 21, 2013

 
Ganymed’s IMAB362 Receives Orphan Drug Designation from FDA and EMA
 
 
 

RELATED ARTICLES

Kidney Cancer Driver Could Lead to New Treatment Strategy

News

Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.

READ MORE

Why Might Super-Tasters be at Higher Cancer Risk?

News

High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been tracked for about 20 years.

READ MORE

Doctors Rely on More Than Just Data During a Diagnosis

News

Computer scientists examine how a doctor’s “gut feeling” influences how many tests they order for patients

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy